Tell your friends about this item:
Biosimilarity: The FDA Perspective
Sarfaraz K. Niazi
Our customers say:
Add to your iMusic wish list
Also available as:
Biosimilarity: The FDA Perspective
Sarfaraz K. Niazi
The focus of this book is on how the US FDA will approve biosimilar drugs. The European scene is well developed with specific guidelines that are already in place. However, these guidelines do not apply to the thinking of the FDA in approving these products.
436 pages
| Media | Books Paperback Book (Book with soft cover and glued back) |
| Released | October 2, 2023 |
| ISBN13 | 9781032652351 |
| Publishers | Taylor & Francis Ltd |
| Pages | 436 |
| Dimensions | 1 kg |
Show all
More by Sarfaraz K. Niazi
See all of Sarfaraz K. Niazi ( e.g. Paperback Book , Hardcover Book , Book and Book pack )